Literature DB >> 26880464

Ipilimumab-associated minimal-change disease.

Jason M Kidd1, Andinet B Gizaw2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26880464     DOI： 10.1016/j.kint.2015.11.028

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  20 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 2.  Renal complications of immune checkpoint blockade.

Authors:  Naoka Murakami; Shveta Motwani; Leonardo V Riella
Journal:  Curr Probl Cancer       Date:  2016-12-19       Impact factor: 3.187

3.  Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?

Authors:  Erin Vaughan; Elizabeth Connolly; Mun Hui; Steven Chadban
Journal:  Cancer Rep (Hoboken)       Date:  2020-06-29

Review 4.  Kidney Complications of Immune Checkpoint Inhibitors: A Review.

Authors:  Roman Shingarev; Ilya G Glezerman
Journal:  Am J Kidney Dis       Date:  2019-07-11       Impact factor: 8.860

Review 5.  Renal Toxicity.

Authors:  Maen Abdelrahim; Ala Abudayyeh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma.

Authors:  Keiko Wakabayashi; Satoko Yamamoto; Shigeo Hara; Momoko Okawara; Kumie Teramoto; Natsuko Ikeda; Yasuo Kusunoki; Masanobu Takeji
Journal:  CEN Case Rep       Date:  2021-09-15

7.  The Role of Kidney Biopsy in Immune Checkpoint Inhibitor-Associated AKI.

Authors:  Arash Rashidi; Chintan Shah; Miroslav Sekulic
Journal:  Kidney360       Date:  2022-01-13

8.  Acute interstitial nephritis related to immune checkpoint inhibitors.

Authors:  Julie Belliere; Nicolas Meyer; Julien Mazieres; Sylvie Ollier; Serge Boulinguez; Audrey Delas; David Ribes; Stanislas Faguer
Journal:  Br J Cancer       Date:  2016-11-10       Impact factor: 7.640

9.  Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.

Authors:  Kang Liu; Zhongke Qin; Xueqiang Xu; Ting Li; Yifei Ge; Huijuan Mao; Changying Xing
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

10.  Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.

Authors:  Angelika Bickel; Irene Koneth; Annette Enzler-Tschudy; Jörg Neuweiler; Lukas Flatz; Martin Früh
Journal:  BMC Cancer       Date:  2016-08-19       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.